A few years ago I had a chance to do a half-day event in Lon­don with a top group of biotech ex­ecs, and I’ve been mean­ing to get back to the Gold­en Tri­an­gle for a re­turn event ever since.

Now, with the Great Around the Biotech World Trip I’m plan­ning for Oc­to­ber, that time has ar­rived.

On Oc­to­ber 10, I’m bring­ing to­geth­er a great group of lead­ers in the biotech com­mu­ni­ty for the first an­nu­al End­points News UK Bio­phar­ma Re­search & De­vel­op­ment Sum­mit, host­ed at the Sil­i­con Val­ley Bank au­di­to­ri­um in Lon­don. 

We’ll be cov­er­ing key is­sues like fi­nanc­ing trends, the ROI of drug de­vel­op­ment and new in­no­va­tion, and how top can­cer drug de­vel­op­ers in the coun­try are nav­i­gat­ing the huge burst of new stud­ies that has swelled the pipeline in re­cent years.

Mene Pan­ga­los

My pan­elists in­clude Mene Pan­ga­los, the EVP of In­no­v­a­tive Med­i­cines, at As­traZeneca; Tim Haines

Kate Bing­ham

from Abing­worth; Kate Bing­ham at SV Health In­vestors; John Pot­tage, CSO at Vi­iV; Nooman Haque at SVB; David Grainger at Medicxi; Jack­ie Hunter from Benev­o­len­tAI; Mike Rea from IDEA; Mal­colm Weir, CEO at Hep­tares; Niall Mar­tin, CEO from Ar­tios and David Chiswell, the leg­endary CAT co-founder who now helms Kymab.

Plus a few we have yet to name.

You can read all about the half-day agen­da here. If you want­ed me to sum up the ob­jec­tive here, I’d say I’m look­ing for a clear up­date on the Gold­en Tri­an­gle’s place in this fast-chang­ing biotech world, with in­vestors act­ing more bull­ish­ly than I’ve ever seen. And I’d like to show the bio­phar­ma world what it looks like from the per­spec­tive of some of the bright­est peo­ple in the field.

We have a lim­it­ed num­ber of seats avail­able for an event that will be record­ed for a lat­er broad­cast. And I’m look­ing for an au­di­ence as great as the pan­elists who are ap­pear­ing to dis­cuss cur­rent biotech events at the sum­mit. Bio­phar­ma ex­ecs look­ing to get in­to the con­ver­sa­tion are hearti­ly wel­come. Plus, we have a beer and wine mix­er at the end, which should be fun.

It’s a good thing that we are near­ly squared away on Lon­don, be­cause af­ter a quick trip to Mu­nich for ES­MO, I’ll be head­ed out to Shang­hai for a 2-day event we’re man­ag­ing with our part­ners in Chi­na, Pharm­Cube: US-Chi­na Bio­phar­ma In­no­va­tion & In­vest­ment Sum­mit. We’re still bring­ing to­geth­er the pan­els for this, but we have head­line events planned with en­tre­pre­neur Saman­tha Du, CEO of Zai Labs, Vivek Ra­maswamy from Roivant, John Oyler, the CEO at BeiGene, Jonathan Wang from Or­biMed Asia and Fa­heem Has­nain, co-founder and ex­ec­u­tive chair­man of Gos­samer, who you may re­call arranged the $7.2 bil­lion sale of Re­cep­tos to Cel­gene and re­cent­ly raised $330 mil­lion for his new ven­ture. 

Plus, we have lots and lots more ex­ecs who will be join­ing us.

We’re go­ing to be talk­ing deals, dol­lars and ren­min­bi at a cru­cial in­ter­sec­tion for US, Chi­nese and Eu­ro­pean play­ers. So why are we ask­ing you to join us? By in­ter­min­gling key play­ers on both sides of the Pa­cif­ic — as well as from Eu­rope — we’d like to spark some new talks on col­lab­o­ra­tions, de­vel­op­ment deals and fi­nanc­ing op­por­tu­ni­ties. Chi­na’s fast-grow­ing in­dus­try is chang­ing every­thing about the glob­al in­dus­try, and this is the time to ful­ly ex­plore it and make some con­nec­tions.

Fi­nal­ly, I’ll be head­ed down to Aus­tralia to keynote the an­nu­al Aus­Biotech gath­er­ing, which I’m re­al­ly look­ing for­ward to. And then I plan to sleep on the en­tire trip back to Ver­mont.

You may have no­ticed that our mot­to here is End­points News: The bio­phar­ma world is here. We weren’t kid­ding around.

A small, Santa Ana-based biotech created in 2017 is looking to enter a SPAC deal as it lays out plans to begin trials in its lead cell therapy candidates and bring on new executives.

Graf Acquisition Corp. IV and NKGen Biotech announced Thursday, with few other details, that the two companies signed a non-binding letter of intent to “pursue a business combination.” Graf Acquisition II and III withdrew their IPOs last year.

The FDA has rejected Incyte’s extended-release formulation of ruxolitinib tablets, in a surprise setback for the company’s plans to build on its blockbuster Jakafi franchise.

The ruxolitinib XR tablets are designed to be taken once a day, whereas Jakafi is indicated for twice daily dosage (although some patients can take it once daily).

According to Incyte, the FDA acknowledged in its complete response letter that the study submitted in the NDA “met its objective of bioequivalence based on area under the curve (AUC) parameters but identified additional requirements for approval.”

Cyclerion Therapeutics may have the design of a Phase IIb study ready to go, but it’s scrambling for a way to fund it.

The company said in a press release that it’s “actively evaluating the best combination of capital, capabilities, and transactions available to it to advance the development of zagociguat,” its lead candidate for a rare, genetic mitochondrial disease known as MELAS.

In a separate SEC filing, Cyclerion once again flagged “substantial doubt about (its) ability to continue as a going concern.” As of the end of 2022, it had cash and cash equivalents of only $13.4 million.